CompanyGraphAt a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $18.37M, above the global median of $16.24M
- FinancialsAltman Z-Score 3.72: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%
Annual Rate
CNY 0.02Paid unknown
Payout Ratio
33.4%Sustainable
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.46BCNY1.11B · vs all stocks (USD)
Trailing P/E
116.29xvs Medical Devices peers
Revenue (TTM)
2.06BCNY305.78M · vs all stocks (USD)
Profit Margin
3.60%vs Medical Devices peers
52-Week Change
-4.67%vs all stocks
Market Capitalization
7.46BCNY1.11B · vs all stocks (USD)
Enterprise Value
7.52BCNY1.12B · vs all stocks (USD)
Trailing P/E
116.29xvs Medical Devices peers
Forward P/E
32.56xvs Medical Devices peers
Price to Sales (TTM)
3.85xvs Medical Devices peers
Price to Book (MRQ)
3.14xvs Medical Devices peers
Enterprise to Revenue
3.65xvs Medical Devices peers
Enterprise to EBITDA
24.74xvs Medical Devices peers
Gross Margin
24.48%vs Medical Devices peers
Profit Margin
3.60%vs Medical Devices peers
Operating Margin
14.41%vs Medical Devices peers
Return on Assets (TTM)
3.60%vs Medical Devices peers
Return on Equity (TTM)
4.29%vs Medical Devices peers
Revenue (TTM)
2.06BCNY305.78M · vs all stocks (USD)
Revenue per Share (TTM)
2.08CNYUpdated Aug 19, 2026Quarterly Revenue Growth
19.80%vs Medical Devices peers
Gross Profit (TTM)
570.82MCNY84.78M · vs all stocks (USD)
EBITDA (TTM)
227.15MCNY33.74M · vs all stocks (USD)
Net Income (TTM)
74.11MCNY11.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
30.80%vs Medical Devices peers
Operating Cash Flow (TTM)
477.87MCNY70.97M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
123.67MCNY18.37M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0190CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.23%vs all stocks
Payout Ratio
33.41%vs Medical Devices peers
Minority Interest (Equity)
104.03MCNYFY2025 · Dec 31, 2025Revenue
1.89BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.37BCNYFY2025 · Dec 31, 2025Gross Profit
510.93MCNYFY2025 · Dec 31, 2025Operating Income
231.36MCNY34.36M · vs all stocks (USD)
Pre-tax Income
151.64MCNYFY2025 · Dec 31, 2025Income Tax Expense
64.29MCNYFY2025 · Dec 31, 2025Net Income
87.35MCNYFY2025 · Dec 31, 2025EBIT
171.30MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
343.56MCNYFY2025 · Dec 31, 2025Research & Development
49.19MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
59.09MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
19.66MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
87.35MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-18.81MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
133.01MCNYFY2025 · Dec 31, 2025Free Cash Flow
-93.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.06BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
87.35MCNYFY2025 · Dec 31, 2025Other Non-cash Items
32.44MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.32MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
10.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-226.53MCNYFY2025 · Dec 31, 2025Net Acquisitions
-368.78MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.82BCNYFY2025 · Dec 31, 2025Sale of Investments
1.75BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-672.57MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
368.89MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-123.03MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-10.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-68.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
167.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
974.29MSharesUpdated Aug 19, 2026Float Shares
469.66MSharesUpdated Aug 19, 2026% Held by Insiders
57.33%vs all stocks
% Held by Institutions
2.09%vs all stocks
Total Cash (MRQ)
1.25BCNY185.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.29CNYUpdated Aug 19, 2026Total Debt (MRQ)
833.42MCNY123.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3411xvs Medical Devices peers
Current Ratio (MRQ)
2.38xvs Medical Devices peers
Book Value per Share (MRQ)
2.59CNYUpdated Aug 19, 2026Total Assets
4.19BCNY622.68M · vs all stocks (USD)
Total Current Assets
1.83BCNYFY2025 · Dec 31, 2025Total Liabilities
1.58BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.36BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
692.89MCNYFY2025 · Dec 31, 2025Total Current Liabilities
883.34MCNYFY2025 · Dec 31, 2025Cash
1.07BCNYFY2025 · Dec 31, 2025Cash Equivalents
195.94KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.07BCNYFY2025 · Dec 31, 2025Other Short-term Investments
199.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
297.97MCNYFY2025 · Dec 31, 2025Inventory
87.16MCNYFY2025 · Dec 31, 2025Accounts Payable
271.43MCNYFY2025 · Dec 31, 2025Short-term Debt
163.57MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.99MCNYFY2025 · Dec 31, 2025Long-term Debt
607.35MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
9.46MCNYFY2025 · Dec 31, 2025Common Stock (Book)
749.45MCNYFY2025 · Dec 31, 2025Retained Earnings
70.29MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.62BCNY388.58M · vs all stocks (USD)
Treasury Stock
38.24MCNYFY2025 · Dec 31, 202552-Week Low
6.40CNYUpdated Aug 19, 202652-Week High
11.06CNYUpdated Aug 19, 202652-Week Change
-4.67%vs all stocks
50-Day MA
7.19CNYUpdated Aug 19, 2026200-Day MA
8.30CNYUpdated Aug 19, 2026Avg 10-Day Volume
18.68MSharesUpdated Aug 19, 2026Avg 30-Day Volume
15.43MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.0700CNYUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.72: safe zoneNotable
Altman Z-Score: 3.72
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $18.37M, above the global median of $16.24MNotable
Levered free cash flow (USD): 18,367,467.212Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Yinchuan Xinhua Commercial Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability
Sinopec Oilfield Service Corporation
2 interpretationsPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability
China Oilfield Services Limited
2 interpretationsPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability